(PID). I-IDSOG-USA advocates the following changes when the guidelines are revised. We recommend the use of the term "upper genital tract infection" (UGTI), followed by the designation of the etiologic agent, instead of the currently employed term, "pelvic inflammatory disease," or PID. In diagnoses, there should be greater emphasis on signs and symptoms related to subclinical or occult UGTI. Therapeutic recommendation for the treatment of UGTI should be documented for various stages of this diverse disease entity. There should be greater emphasis on hospitalization for infected nulligravida teenagers. This permits monitoring of antibiotic treatment and provides a site for medical educational efforts to teach this medically underserved segment of our society how to protect their future fertility, their health, and their lives.
Since the early 1980s, key members of the infectious disease societies within the discipline of Obstetrics and Gynecology have lobbied to change or redefine the term "pelvic inflammatory disease" (PID) and to develop more precise therapeutic strategies for this condition [1] . Analysis of current strategies has focused on the Centers for Disease Control and Prevention (CDC) definition of PID and its diagnostic and therapeutic ramifications [2] . Because of the fiscal and logistical limitations imposed on the CDC, meaningful reanalysis of material published in guidelines for the treatment of sexually transmitted diseases has historically occurred at 3-5-year intervals. In an effort to address the serious problem of PID and its sequelae, the International-Infectious Disease Society for Obstetrics and Gynecology-USA (I-IDSOG-USA) convened a meeting of expert physicians in the field of PID to further review the literature and formulate the clinical opinions that subsequently were presented and ratified by I-IDSOG-USA in May 1999.
WHAT IS PID?
The CDC definition of PID as published in Morbidity and Mortality Weekly Report reads as follows:
PID comprises a spectrum of inflammatory disorders of the upper female genital tract, including any combination of endometritis salpingitis, tubo-ovarian abscess, and pelvic peritonitis. Sexually transmitted organisms, especially Neisseria gonorrhoeae and Chlamydia trachomatis are implicated in most cases, however, microorganisms that can be part of the vaginal flora (e.g., anaerobes Gardnerella vaginalis, Haemophilus influenzae, enteric Gram-negative rods, and Streptococcus agalactiae) can also cause PID. In addition, M. hominis and U. urealyticum might be etiological agents of PID. [2, p. 79].
I-IDSOG-USA DEFINITION OF PID
The purpose of nomenclature should be to communicate clearly. The term "PID" encompasses a multitude of entities, the pathogenesis and outcome of which may differ significantly. The membership of I-IDSOG-USA strongly recommends eliminating the term PID and replacing it with the term "upper genital tract infection" (UGTI). However, recognizing that the term PID is too ingrained in medical circles, and recognizing that the educational effort necessary to produce change would be cumbersome and to a degree counterproductive, the committee advocated retaining the term PID in a modified form for current use, provided that there is commitment to its eventual replacement. In order for the designation "PID" to communicate specific content and not merely be a diagnostic catch-all, it should incorporate aspects that aid in projecting unity of thought concerning anatomical, etiological, and epidemiological characteristics.
Anatomical designations. The term PID indicates an inflammatory process of infectious etiology involving, at the least, the endometrium and fallopian tubes.
Etiological and epidemiological designation. The members of the I-ID-SOG-USA concur with the designation of Neisseria gonorrhoeae and Chlamydia trachomatis as initiating cytological agents. Inclusion of anaerobic bacteria, Gardnerella vaginalis, Haemophilus influenzae, gram-negative rods, and other bacteria as causative as opposed to contributing organisms is not supported by the literature [2] [3] [4] [5] [6] [7] [8] . Concern was expressed that the decision to include them in the definition might seem to be rehashing the controversy over the definitions of polymicrobial and anaerobic superinfection that ended in the 1970s [3, 6, 8] . I-IDSOG-USA advocates that the etiology designated by the term PID be restricted to initiating organisms that share a common mode of dissemination and demographic profile and that are capable of producing relatively comparable long-term sequelae.
This combination of criteria precludes characterizing disease due to rare monoetiological pathogens such as Streptococci pneumoniae, group A streptococcus, and Neisseria meningitidis as PID. Instead, the disease entity caused by these organisms would be labeled as upper genital tract disease due to the relevant bacteria (i.e., UGTI due to group A streptococcus).
Until it is replaced by a more precise definition, the following is the I-IDSOG-USA definition of PID: Pelvic inflammatory disease is an inflammatory process of infectious etiology which shares a common epidemiological profile, which specifically involves at the least the uterine and/or fallopian tube sites, and which may result in relatively comparable long term sequelae. Disease due to bacteria not meeting these requirements will be termed upper female genital tract infection (UFGTI or UGTI) and the designation of specific etiology cited.
In the future, through a concerted educational effort, the I-IDSOG-USA will replace this new restructured definition for PID with the term "upper female genital tract infection," followed by the name of the etiological agent, followed by the stage of disease (e.g., UGTI, Neisseria gonorrhoeae, stage III).
DIAGNOSTIC SHORTCOMINGS
The conceptual term PID has had negative consequences on the diagnosis of sexually transmitted disease (STD) UGTI. The CDC's published diagnostic recommendations focused primarily on acute salpingitis, to the detriment of chlamydial UGTI (table 1) . If the term PID is to be retained, greater emphasis needs to be placed on the more occult and destructive subacute forms of upper genital tract disease.
The membership of I-IDSOG-USA advocates the following changes in the diagnosis of PID. (1) Symptoms should be included that are associated with an increased possibility of occult upper female genital tract infection. More attention needs to be given to symptoms associated with occult chlamydial infection, such as intermenstrual spotting, abnormal vaginal discharge or urinary frequency, or symptomatology of chlamydial or gonococcal endocervicitis or urethritis, which may lead to the identification of concomitant endometritis and possibly salpingitis. (2) Greater emphasis should be placed on the diagnostic use of endometrial smears obtained with a sheath or unsheathed swab to demonstrate the presence of a predominately mononuclear cell exudate. Considerations should be given to the evidence of inflammation from endocervical cytological smears obtained from a patient whose previous smears lacked this finding.
DEFINING AN APPROPRIATE END POINT FOR THERAPY
Studies from the late 1970s demonstrated that acute salpingitis caused by N. gonorrhoeae, with or without the concomitant chlamydial infection, is a dynamic process. The inflammatory process initiated by the gonococcus recruited initially aerobic and ultimately anaerobic bacteria (anaerobic progression) into the mechanistic aspects of disease [4, [8] [9] [10] [11] [12] . What began as a primarily monomicrobial process ultimately became a polymicrobial infection through the process of endogenous superinfection [7] [8] [9] . Previous studies have demonstrated that the bacteria isolated from the fallopian tubes, not the cervix, appears to govern therapeutic responsiveness [11] . When N. gonorrhoeae was the sole isolate from the culde-sac of an infected woman, a precise anticipated therapeutic response was discernible in women with acute gonococcal salpingitis with or without gonococcal peritonitis, namely (1) resolution of fever in р36 h (usually !24 h); (2) disappearance of signs of peritoneal irritation and marked diminution of deep organ tenderness in р36 h; and (3) a normal WBC count within р48 h (usually !24 h) [11] . However, if the gonococcus was a constituent of a polymicrobial peritonitis, the therapeutic response was often altered, unless most of the organisms present were susceptible to the antibiotic regimen that was administered. Longterm follow-up showed that patients who had significantly altered therapeutic responses had a significantly higher incidence of secondary fertility than patients who had prompt responses [12] [13] [14] . When the anaerobic progression resulted in autoelimination of the gonococcus within the cul-de-sac, it was difficult to achieve a good therapeutic response with antibiotics whose primary spectrum of efficacy focused on N. gonorrhoeae and C. trachomatis.
Advances in therapeutics for pelvic infection are contingent on understanding the dynamic changes required. What may be excellent therapy for early gonococcal disease might guarantee unwanted future infertility or increased potential for ectopic pregnancies if used as therapy for disease at the wrong stage (Ortho-McNeil Pharmaceutical, personal communication) [11, 14] . Therapeutic requisites for a tubo-ovarian complex or tubo-ovarian abscess are distinctly different from those for early monoetiological gonococcal disease. Although internal auto-elimination of the gonococcus occurs first in the culde-sac, a comparable process will ultimately occur at the endocervix, resulting in nonrecovery either because of technique error when !10 3 cfu per milliliter of organism are present, or because of complete autoelimination of the gonococcus from the endocervix.
Cunningham et al. [14] demonstrated an 86% response rate within 3 days when the gonococcus was present at the endocervix, in contrast to a 74% response rate when it was absent. Thompson et al. [15] reported a change of severity score by the fourth day in 73% of patients in whom the gonococcus was present at the endocervix, but only in 45% of patients in whom it was not. In a large CDCsponsored collaborative study of patients in whom the gonococcus was present at the endocervix, the investigators found a 13.8% failure rate, in contrast to a 17% failure rate when the gonococcus was not present at the endocervix [15] . The existing CDC definition of PID, whereby all stages, severities, and etiologies of PID are lumped together for both diagnostic and treatment recommendations, has been a severe barrier to effectively identifying and addressing the therapeutic requirements of specific types of PID.
NEED TO DEFINE STAGES OF ACUTE DISEASE
The ability to anticipate the anticipated therapeutic response in patients with acute salpingitis requires a recognition of the dynamics that change the therapeutic requirements [9] [10] [11] . As a consequence, I-IDSOG-USA recommends the adoption of the following definitions of the stages of acute UGTI:
Women who fulfill the CDC major diagnostic criteria and у1 of its minor criteria but who do not have overt peritonitis (as demonstrated by the absence of rebound tenderness) and who have not had any Stage III.
Women with demonstrable tubo-ovarian complex or tuboovarian abscess evident on either physical or ultrasonographic examination.
Stage IV. Women with ruptured tubo-ovarian abscesses.
Patients who have an intrauterine contraceptive device or have previously had episodes of UGTI require individualized staging within this schema.
The demonstration that the stage of disease can markedly influence the therapeutic responsiveness also needs to influence how the pharmaceutical industry presents data to the US Food and Drug Administration (FDA) and the CDC. Lumping all stages of acute salpingitis into a single category designation facilitates obtaining an indication for PID; however, the antibiotic in question might be less than optimal for advanced stage II disease with a low oxidation/reduction potential and anaerobic superinfection or for stage III or stage IV disease.
A case in point was the ability of ofloxacin to be presented to physicians by its manufacturer as "an antibiotic for severe pelvic inflammatory disease" despite its limited spectrum of activity against anaerobic bacteria (Ortho-McNeil Pharmaceutical, personal communication). Ofloxacin appears to be an effective antibiotic for stage I and probably stage II disease, but on theoretical grounds, it lacks the critical anaerobic coverage necessary for late stage II or stage III disease.
The I-IDSOG-USA strongly advocates that, for a drug to obtain FDA approval, data regarding its efficacy be broken down according to the specific stages of disease and the ability of the drug to approximate the anticipated therapeutic response for that stage of disease.
The central issue of therapy of acute salpingitis is "the preservation of the fallopian tube structure and function." Priority should be given to therapeutic regimens that have documented their superiority for a specific stage of disease, rather than for the catch-all term PID, because diagnosis of PID is related to STD pathogens.
WHO IS TO BE HOSPITALIZED?
Because of the lack of data regarding criteria for hospitalization versus ambulatory care, the CDC has not been able to formulate data-based recommendations as to what patients should be hospitalized with STD upper genital tract disease. Published guidelines dealing with patients selected for ambulatory care for acute salpingitis are exceedingly few. In 1987, Sweet [16] published criteria for hospitalization of women with PID (table  2) . Subsequently, Monif [17] described criteria for the selection of candidates for ambulatory care of acute gonococcal salpingitis (table 3) .
Although the criteria for hospitalization are the converse of the criteria for selection for ambulatory care, the 2 sets of criteria mesh surprisingly well. Where they differ slightly is in the concern over the magnitude of the patient's fever. In many instances, low fever or the absence of fever indicates more advanced disease. Markedly elevated temperatures are more common with monoetiological gonococcal infections and correlate with a better prognosis if effective therapy is instituted early.
In recent times, recommendations for management have tended to be based on cost considerations. Acknowledging that documentation is poor, I-IDSOG-USA makes the following recommendation, which is based on advocacy for women: that all teenage nulligravida girls with acute salpingitis, irrespective of stage of disease, should be hospitalized, and that the period of hospitalization should allow for both therapy and education about the entire spectrum of sexually transmitted diseases. In their assessment of adolescents with PID requiring hospitalization, Gonik et al. [18] noted a pattern of poor contraceptive use, frequent venereal disease exposure, delayed presentation for medical care, and high antimicrobial failure rate. Fifty percent of adolescents with advanced disease failed to return for follow-up care after discharge. The authors suggested that adolescent girls commonly worsen their own prognoses because they deny symptomatology, fear parental discovery, have limited financial resources, or experience peer pressure. Even adolescents with early stage I disease present to the health care provider in an emotional and physical state that can enhance educational communication concerning STDs.
The I-IDSOG-USA criteria governing patient selection for ambulatory care of acute salpingitis are listed in table 4 . If the issue of future fertility is a consideration, I-IDSOG-USA's recommendation is to offer and counsel hospitalization for all women with acute gonococcal salpingitis. Even when other ambulatory care criteria are met, hospitalization is adamantly advocated for all adolescents and all nulligravida young women, especially teenagers. Hospitalizations should be used as an educational as well as therapeutic vehicle.
